Neuroblastoma - Pipeline Review, H1 2017

  • ID: 4311834
  • Report
  • 417 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • Biotec Pharmacon ASA
  • CorMedix Inc
  • Ignyta Inc
  • Novartis AG
  • Sapience Therapeutics Inc
  • MORE
Neuroblastoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 19, 1, 44, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • Biotec Pharmacon ASA
  • CorMedix Inc
  • Ignyta Inc
  • Novartis AG
  • Sapience Therapeutics Inc
  • MORE
  1. Introduction
  2. Neuroblastoma - Overview
  3. Neuroblastoma - Therapeutics Development
  4. Neuroblastoma - Therapeutics Assessment
  5. Neuroblastoma - Companies Involved in Therapeutics Development
  6. Neuroblastoma - Drug Profiles
  7. Neuroblastoma - Dormant Projects
  8. Neuroblastoma - Discontinued Products
  9. Neuroblastoma - Product Development Milestones
  10. Appendix
List of Tables:
  1. Number of Products under Development for Neuroblastoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Companies, H1 2017 (Contd..2), H1
  5. Number of Products under Development by Companies, H1 2017 (Contd..3), H1
  6. Number of Products under Development by Universities/Institutes, H1
  7. Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
  8. Products under Development by Companies, H1
  9. Products under Development by Companies, H1 2017 (Contd..1), H1
  10. Products under Development by Companies, H1 2017 (Contd..2), H1
  11. Products under Development by Companies, H1 2017 (Contd..3), H1
  12. Products under Development by Companies, H1 2017 (Contd..4), H1
  13. Products under Development by Universities/Institutes, H1
  14. Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
  15. Number of Products by Stage and Target, H1
  16. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  17. Number of Products by Stage and Target, H1 2017 (Contd..2), H1
  18. Number of Products by Stage and Target, H1 2017 (Contd..3), H1
  19. Number of Products by Stage and Mechanism of Action, H1
  20. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  21. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1
  22. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1
  23. Number of Products by Stage and Route of Administration, H1
  24. Number of Products by Stage and Molecule Type, H1
  25. Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1
  26. Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1
  27. Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1
  28. Neuroblastoma - Pipeline by Alissa Pharma, H1
  29. Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1
  30. Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H1
  31. Neuroblastoma - Pipeline by APEIRON Biologics AG, H1
  32. Neuroblastoma - Pipeline by AstraZeneca Plc, H1
  33. Neuroblastoma - Pipeline by Bayer AG, H1
  34. Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1
  35. Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1
  36. Neuroblastoma - Pipeline by BioLineRx Ltd, H1
  37. Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1
  38. Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1
  39. Neuroblastoma - Pipeline by Bristol-Myers Squibb Company, H1
  40. Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1
  41. Neuroblastoma - Pipeline by Cebiotex SL, H1
  42. Neuroblastoma - Pipeline by Celgene Corp, H1
  43. Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1
  44. Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1
  45. Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1
  46. Neuroblastoma - Pipeline by CorMedix Inc, H1
  47. Neuroblastoma - Pipeline by Curis Inc, H1
  48. Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1
  49. Neuroblastoma - Pipeline by DEKK-TEC Inc, H1
  50. Neuroblastoma - Pipeline by EnGeneIC Ltd, H1
  51. Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1
  52. Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1
  53. Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1
  54. Neuroblastoma - Pipeline by Green Cross Cell Corp, H1
  55. Neuroblastoma - Pipeline by Ignyta Inc, H1
  56. Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1
  57. Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1
  58. Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1
  59. Neuroblastoma - Pipeline by MacroGenics Inc, H1
  60. Neuroblastoma - Pipeline by MediaPharma srl, H1
  61. Neuroblastoma - Pipeline by Merck & Co Inc, H1
  62. Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H1
  63. Neuroblastoma - Pipeline by Morphogenesis Inc, H1
  64. Neuroblastoma - Pipeline by Novartis AG, H1
  65. Neuroblastoma - Pipeline by Novogen Ltd, H1
  66. Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1
  67. Neuroblastoma - Pipeline by Pfizer Inc, H1
  68. Neuroblastoma - Pipeline by Phylogica Ltd, H1
  69. Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1
  70. Neuroblastoma - Pipeline by Recombio SL, H1
  71. Neuroblastoma - Pipeline by Ribomic Inc, H1
  72. Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1
  73. Neuroblastoma - Pipeline by Sareum Holdings Plc, H1
  74. Neuroblastoma - Pipeline by Shionogi & Co Ltd, H1
  75. Neuroblastoma - Pipeline by Sierra Oncology Inc, H1
  76. Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1
  77. Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H1
  78. Neuroblastoma - Pipeline by Trovagene Inc, H1
  79. Neuroblastoma - Dormant Projects, H1
  80. Neuroblastoma - Dormant Projects, H1 2017 (Contd..1), H1
  81. Neuroblastoma - Dormant Projects, H1 2017 (Contd..2), H1
  82. Neuroblastoma - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Neuroblastoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Top 10 Molecule Types, H1
  11. Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ability Pharmaceuticals SL
  • Actuate Therapeutics Inc
  • Advanced Accelerator Applications SA
  • Alissa Pharma
  • Ampio Pharmaceuticals Inc
  • APAvadis Biotechnologies Srl
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bexion Pharmaceuticals LLC
  • BioLineRx Ltd
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cancer Prevention Pharmaceuticals Inc
  • Cebiotex SL
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cielo Therapeutics Inc
  • Cleveland BioLabs Inc
  • CorMedix Inc
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • DEKK-TEC Inc
  • EnGeneIC Ltd
  • Errant Gene Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Green Cross Cell Corp
  • Ignyta Inc
  • Juno Therapeutics Inc
  • Lindis Biotech GmbH
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • MediaPharma srl
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • Morphogenesis Inc
  • Novartis AG
  • Novogen Ltd
  • OGD2 Pharma SAS
  • Pfizer Inc
  • Phylogica Ltd
  • Progenics Pharmaceuticals Inc
  • Recombio SL
  • Ribomic Inc
  • Sapience Therapeutics Inc
  • Sareum Holdings Plc
  • Shionogi & Co Ltd
  • Sierra Oncology Inc
  • Syros Pharmaceuticals Inc
  • Tiltan Pharma Ltd
  • Trovagene Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll